Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Lilly Asia Ventures

Lilly Asia Ventures

Lilly Asia Ventures or LAV is a venture capital firm investing in biomedical companies.

Lilly Asia Ventures is a venture capital firm. The firm makes venture capital investments in the life sciences and healthcare sectors in Asia, with a focus on China. It was founded in 2008 and is based in Shanghai, China.

Lilly Asia Ventures wants to become the partner for entrepreneurs seeking capital and to build great companies developing products that treat diseases and improve human health.

Lilly Asia Ventures originated as a corporate venture subsidiary of Eli Lilly, until they spun off and became an independent investment management company. They manage over $1.2 billion of committed capital.

Timeline

Invested in

Associated Investment Funds

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 10, 2021
FierceBiotech
OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals' $75 million series B round. The funding will take the San Diego-based biotech's growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday.
FinSMEs
May 10, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Alebund Pharmaceuticals
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the...
Regor Therapeutics Group
February 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders...
November 27, 2020
BioSpace
Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.